Certolizumab to treat hidradenitis suppurativa
https://doi.org/10.4081/dr.2022.9566
HTML: 18
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition that affects apocrine gland-bearing skin. The management of HS with biologics has expanded significantly over the past few years. Certolizumab pegol is a pegylated (polyethylene glycol) antigen-binding fragment of a recombinant humanized anti-TNF-α monoclonal antibody, which is approved for psoriasis, rheumatoid arthritis, ankylosing spondylitis, and Crohn’s disease. In recent years many reports have been merging on the use of certolizumab in treating hidradenitis suppurativa. The electronic database MEDLINE was searched through PubMed in February 2022 using the following search terms: Certolizumab “[All Fields] OR” certolizumab pegol”[All Fields] AND “Hidradenitis suppurativa”[ All Fields]. The search revealed that certolizumab was used in 6 case reports to treat HS with a total of 7 patients. We can conclude that there are few cases in the literature discussing the use of certolizumab in HS, all of which, show a good and promising response with no reported side effects.
Nguyen TV, Damiani G, Orenstein LA, et al. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 2021;35:50-61.
Jfri A, Nassim D, O’Brien E, et al. Prevalence of Hidradenitis suppurativa: a systematic review and meta-regression analysis. JAMA Dermatol 2021;157:924-31.
Capasso G, Fabbrocini G, Marasca C. Disfiguring hidradenitis suppurativa of the face. Skin Appendage Disord 2022;8:70-2.
Anduquia-Garay F, Rodríguez-Gutiérrez MM, Poveda-Castillo IT, et al. Hidradenitis suppurativa: basic considerations for its approach: a narrative review. Ann Med Surg 2021;68:102679.
Flood KS, Porter ML, Kimball AB. Biologic treatment for hidradenitis suppurativa. Am J Clin Dermatol 2019;20:625-38.
Collier EK, Seivright JR, Shi VY, Hsiao JL. Pregnancy and breastfeeding in hidradenitis suppurativa: a review of medication safety. Dermatol Ther 2021;34:e14674.
Repetto F, Burzi L, Ramondetta A, et al. Certolizumab pegol and its role in pregnancy-age hidradenitis suppurativa. Int J Dermatol 2022;61:e182-4.
Esme P, Akoglu G, Caliskan E. Rapid response to certolizumab pegol in hidradenitis suppurativa: a case report. Skin Appendage Disord 2021;7:58-61.
Tampouratzi E, Kanni T, Katsantonis J, Douvali T. Case report: treating a co-existence of hidradenitis suppurativa and psoriasis with different therapeutic approaches. F1000Res 2019;8:2002.
Holm JG, Jørgensen AH, Yao Y, Thomsen SF. Certolizumab pegol for hidradenitis suppurativa: case report and literature review. Dermatol Ther 2020; 33:e14494.
Wohlmuth-Wieser I, Alhusayen R. Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. Int J Dermatol 2021;60:e140-1.
Abad JS. A case report of hidradenitis suppurativa treated with certolizumab. JAAD 2019;81.
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
